Enhanced Aminos Back to Inventory
Hormonal

PT-141

Melanocortin Receptor Agonist

PT-141

Dosage

10mg

Unit Size

1 Vial

// Add to Cart

10mg

$40.00

99 in stock

What is PT-141?

PT-141 (bremelanotide) is a cyclic heptapeptide analogue of alpha-melanocyte stimulating hormone, engineered for greater stability and central nervous system access than the native hormone. Research interest centres on its activity at melanocortin receptors in the hypothalamus, where it is studied for effects on desire and arousal pathways rather than on blood flow.

MC4R

Primary Receptor Target

Cyclic

Peptide Structure

Central

Site of Action

Key Benefits

🧠

Central Pathway Activity

Studied for activation of hypothalamic melanocortin signalling rather than peripheral vascular effects.

🔗

MC4R Binding

Cyclic structure binds melanocortin-4 receptors with high affinity in preclinical receptor assays.

âš¡

Dopaminergic Engagement

Downstream of MC4R, research models show engagement of dopamine-linked reward circuitry.

🧬

Stability Profile

The lactam ring bridges the peptide backbone, resisting enzymatic degradation better than linear analogues.

🎯

Desire Pathways

Investigated in models of hypoactive desire as a non-vascular mechanism of action.

🔬

Receptor Selectivity

Binding affinity across melanocortin receptor subtypes is a focal point of characterization work.

How It Works

1

Melanocortin Receptor Binding

PT-141 binds melanocortin receptor subtypes, with MC4R activity in the central nervous system considered the primary driver in published models.

2

Hypothalamic Signalling

Receptor activation in hypothalamic nuclei is studied as the entry point for downstream effects on arousal and desire pathways.

3

Dopamine Pathway Engagement

MC4R activation appears to recruit dopaminergic signalling, which researchers track as a marker of central pathway activity.

4

Cyclic Structure Advantage

The ring-closed backbone limits protease access, which is why the analogue reaches the CNS more reliably than linear MSH fragments.

Common Protocol (Research Reference)

1–2 mg

Study dose

Single dose

Administration model

Acute

Typical study design

Research Use Notice

PT-141 is a research peptide not approved by the FDA for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.